The Third Hospital of Changsha
Changsha, Hunan, 410011, China
NCT Number: NCT06132243
To evaluate the pharmacokinetic Characteristics of two formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Changsha, Hunan, 410011, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Orally, one tablet at a time
Other names: Jaktinib
Time frame: up to 48 hours
Maximum Plasma Concentration (Cmax)
Time frame: up to 48 hours
Area under the concentration time curve from time 0 to time of the last quantifiable
Time frame: up to 48 hours
Area under the concentration time curve from time 0 to infinity
Time frame: up to 48 hours
Maximum Plasma Concentration (Tmax)
Time frame: up to 48 hours
Half Life (t1/2)
Time frame: Day 1 to Day 12
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Industry
A Single-dose, Randomized, Open-label, Repeated Cross-over Pharmacokinetic Comparison Study of Two Formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers Under Fasted Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03480360
Acute Myeloid Leukemia, Anemia
Lebanon, New Hampshire, United States
View Trial DetailsNCT03427866
Bone Marrow Diseases, Hematologic Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT00081874
Bone Marrow Diseases, Chronic Disease
Houston, Texas, United States
View Trial DetailsNCT02158858
Blood Coagulation Disorders, Blood Platelet Disorders
Phoenix, Arizona, United States
View Trial Details